Portal de Periódicos da CAPES

Re: “Moving Forward After Two Deaths in a Gene Therapy Trial of Myotubular Myopathy” by Wilson and Flotte

2020; Mary Ann Liebert, Inc.; Volume: 31; Issue: 15-16 Linguagem: Inglês

10.1089/hum.2020.217

1557-7422

Perry B. Shieh, Carsten G. Bönnemann, Wolfgang Müller‐Felber, Astrid Blaschek, James J. Dowling, Nancy L. Kuntz, A. Seferian,

Genetic Neurodegenerative Diseases

Human Gene TherapyVol. 31, No. 15-16 Letter to the EditorOpen AccessCreative Commons licenseRe: "Moving Forward After Two Deaths in a Gene Therapy Trial of Myotubular Myopathy" by Wilson and FlottePerry B. Shieh, Carsten G. Bönnemann, Wolfgang Müller-Felber, Astrid Blaschek, James J. Dowling, Nancy L. Kuntz, and Andreea M. SeferianPerry B. ShiehCorrespondence: Dr. Perry B. Shieh, 300 Medical Plaza, Suite B-200, Los Angeles, CA 90095, USA. E-mail Address: pshieh@mednet.ucla.eduUniversity of California at Los Angeles School of Medicine, Los Angeles, California, USASearch for more papers by this author, Carsten G. BönnemannNational Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland, USASearch for more papers by this author, Wolfgang Müller-FelberKlinikum der Universität München, Munich, GermanySearch for more papers by this author, Astrid BlaschekKlinikum der Universität München, Munich, GermanySearch for more papers by this author, James J. DowlingHospital for Sick Children, Toronto, Ontario, CanadaSearch for more papers by this author, Nancy L. KuntzAnn and Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, USASearch for more papers by this author, and Andreea M. SeferianInstitute of Myology, Pitié-Salpêtrière Hospital, Paris, France.Search for more papers by this authorPublished Online:17 Aug 2020https://doi.org/10.1089/hum.2020.217AboutSectionsPDF/EPUB Permissions & CitationsPermissionsDownload CitationsTrack CitationsAdd to favorites Back To Publication ShareShare onFacebookTwitterLinked InRedditEmail Dear Editor,In response to the recent editorial, "Moving Forward After Two Deaths in a Gene Therapy Trial of Myotubular Myopathy," and as investigators for the ASPIRO study in children with X-linked myotubular myopathy (XLMTM), we want to clarify discrepancies in the information provided and emphasize several points. We do so in the spirit of transparency for the scientific community that continues to pursue gene therapies to safely improve the lives of patients.ASPIRO is a first-in-human study of intravenously administered AT132, an investigational therapeutic MTM1 (myotubularin) gene transfer using a recombinant AAV8 vector for enhanced muscle transduction and a muscle-specific promoter for tissue-restricted expression. Preclinical studies of AT132 were conducted by Audentes in two animal models of XLMTM (MTM1 knockout mouse and a naturally occurring missense-mutated canine) and in wild-type nonhuman primates (NHPs). These studies showed that doses of AT132 up to 8 × 1014 vg/kg (vector genomes per kg) were well tolerated in NHPs with no adverse findings related to AT132 exposure (unpublished data).Doses for the ASPIRO ascending-dose clinical trial were informed by efficacy and safety observations from those carefully designed animal experiments. Importantly, the hepatotoxicity observed in three boys who received the 3 × 1014 vg/kg dose in ASPIRO was not observed in the XLMTM animals and in NHPs that received 8 × 1014 vg/kg.To date, 17 boys have received AT132 at 3 × 1014 vg/kg, in the initial dose escalation cohort of ASPIRO or in a later expansion cohort, which proceeded after careful assessment of prior dosed patients, including by an independent monitoring committee. Two of the 17 boys who received AT132 at the 3 × 1014 vg/kg dose experienced fatal liver dysfunction and one has ongoing severe liver dysfunction. These three boys, who were in the later expansion cohort, shared several notable features: they were older, heavier (and thus received among the highest total vg, range: 4.80 × 1015–7.74 × 1015 total vg), and all had evidence of likely pre-existing intrahepatic cholestasis. Although the two deaths occurred months after dosing, all three boys demonstrated signs of liver dysfunction within 3–4 weeks after receiving AT132.Although the pathomechanism is not yet characterized, hepatobiliary disease is observed in the XLMTM population.1–3 After treatment with AT132, liver findings in these three boys included intrahepatocellular and canalicular cholestasis, periportal and bile ductular reaction, secondary fibrosis, and notable lack of prominent liver parenchymal inflammatory cellular infiltrates. More than 50% of subjects in the ASPIRO trial have some evidence of pre-existing hepatobiliary disease—including intermittent direct hyperbilirubinemia, intermittent transaminase elevation, and/or historical cholestasis or jaundice—yet no similar, treatment-related, serious cholestatic liver dysfunction has been observed in the six patients in the 1 × 1014 vg/kg cohort or in any of the younger, lighter patients in the 3 × 1014 vg/kg cohort regardless of pre-existing hepatobiliary disease.It is important to evaluate whether immune mechanisms may have contributed to the severe liver dysfunction observed, particularly in light of what has been published for adeno-associated virus-mediated gene therapy across varying serotypes and dose levels, including in preclinical settings. However, full investigations of these events are ongoing, and it is premature to draw definitive conclusions at this time.We have observed favorable efficacy data for gene transfer therapy in murine and canine XLMTM, with neither animal study suggesting adverse findings related to hepatobiliary disease. In 2019, we presented preliminary efficacy and safety data from ASPIRO, highlighting the potential for AT132 to transform the lives of children with this fatal and life-limiting disease.4 As we continue to learn more about all of the patients from ASPIRO, our intention is to publish the full data set as soon as is practicable.These children and their families have indeed shown great bravery. We honor that bravery by exploring the underlying etiology of these events as diligently as possible and remain committed to delivering to them a safe and effective therapy.References1. Amburgey K, Tsuchiya E, de Chastonay S, et al. A natural history study of X-linked myotubular myopathy. Neurology 2017;89:1355–1364. Crossref, Medline, Google Scholar2. Beggs AH, Byrne BJ, de Chastonay S, et al. A multicenter, retrospective medical record review of X-linked myotubular myopathy: the RECENSUS study. Muscle Nerve 2018;57:550–560. Crossref, Medline, Google Scholar3. Herman GE, Finegold M, Zhao W, et al. Medical complications in long-term survivors with X-linked myotubular myopathy. J Pediatr 1999;134:206–214. Crossref, Medline, Google Scholar4. Dowling JJ, Shieh PB, Kuntz NL, et al. The ASPIRO gene therapy trial in X-linked myotubular myopathy (XLMTM): update on preliminary safety and efficacy findings. Presentation at the 24th International Annual Congress of the World Muscle Society, October 1–5, 2019, Copenhagen, Denmark. Google ScholarFiguresReferencesRelatedDetailsCited byMeeting Report: 2022 Muscular Dystrophy Association Summit on 'Safety and Challenges in Gene Transfer Therapy'Journal of Neuromuscular Diseases, Vol. 57Adeno-Associated Virus Gene Therapy for HemophiliaAnnual Review of Medicine, Vol. 74, No. 1Current Strategies of Muscular Dystrophy Therapeutics: An Overview19 November 2022Suppression of heterotopic ossification in fibrodysplasia ossificans progressiva using AAV gene delivery19 October 2022 | Nature Communications, Vol. 13, No. 1Phenotypic Spectrum of DNM2 -Related Centronuclear Myopathy25 October 2022 | Neurology Genetics, Vol. 8, No. 6Evading and overcoming AAV neutralization in gene therapyTrends in Biotechnology, Vol. 21rAAV immunogenicity, toxicity, and durability in 255 clinical trials: A meta-analysis27 October 2022 | Frontiers in Immunology, Vol. 13A systematic review of adeno-associated virus gene therapies in neurology: the need for consistent safety monitoring of a promising treatment8 September 2022 | Journal of Neurology, Neurosurgery & Psychiatry, Vol. 11A versatile toolkit for overcoming AAV immunity2 September 2022 | Frontiers in Immunology, Vol. 13Onasemnogene abeparvovec for the treatment of spinal muscular atrophy2 May 2022 | Expert Opinion on Biological Therapy, Vol. 22, No. 9Adeno-associated virus mediates gene transduction after static cold storage treatment in rodent lung transplantationThe Journal of Thoracic and Cardiovascular Surgery, Vol. 14Immunogenicity assessment of AAV-based gene therapies: An IQ consortium industry white paperMolecular Therapy - Methods & Clinical Development, Vol. 26Gene-based therapeutics for rare genetic neurodevelopmental psychiatric disordersMolecular Therapy, Vol. 30, No. 7Natural history study and statistical modeling of disease progression in a preclinical model of myotubular myopathy25 July 2022 | Disease Models & Mechanisms, Vol. 15, No. 7Immunogenicity of Novel AAV Capsids for Retinal Gene Therapy9 June 2022 | Cells, Vol. 11, No. 12Preclinical assessment of an optimized AAV-FVIII vector in mice and non-human primates for the treatment of hemophilia AMolecular Therapy - Methods & Clinical Development, Vol. 24Gene Therapy Advances: A Meta-Analysis of AAV Usage in Clinical Settings9 February 2022 | Frontiers in Medicine, Vol. 8Gene Therapy Developments for Pompe Disease28 January 2022 | Biomedicines, Vol. 10, No. 2Intrahepatic Cholestasis Is a Clinically Significant Feature Associated with Natural History of X-Linked Myotubular Myopathy (XLMTM): A Case Series and Biopsy ReportJournal of Neuromuscular Diseases, Vol. 9, No. 1Hemophilia gene therapy: ushering in a new treatment paradigm?10 December 2021 | Hematology, Vol. 2021, No. 1In utero adenine base editing corrects multi-organ pathology in a lethal lysosomal storage disease13 July 2021 | Nature Communications, Vol. 12, No. 1Hepatic expression of GAA results in enhanced enzyme bioavailability in mice and non-human primates4 November 2021 | Nature Communications, Vol. 12, No. 1Hepatobiliary disease in XLMTM: a common comorbidity with potential impact on treatment strategies12 October 2021 | Orphanet Journal of Rare Diseases, Vol. 16, No. 1Physical and mechanical cues affecting biomaterial-mediated plasmid DNA delivery: insights into non-viral delivery systems17 June 2021 | Journal of Genetic Engineering and Biotechnology, Vol. 19, No. 1Common Pathogenic Mechanisms in Centronuclear and Myotubular Myopathies and Latest Treatment Advances21 October 2021 | International Journal of Molecular Sciences, Vol. 22, No. 21Adeno-Associated Viruses (AAV) and Host Immunity – A Race Between the Hare and the Hedgehog29 October 2021 | Frontiers in Immunology, Vol. 12Capsid-Engineering for Central Nervous System-Directed Gene Therapy with Adeno-Associated Virus Vectors Josephine Macdonald, Jennifer Marx, and Hildegard Büning18 October 2021 | Human Gene Therapy, Vol. 32, No. 19-20Consequences of Mammalian Target of Rapamycin Inhibition on Adeno-Associated Virus Hepatic Transduction Efficacy Andrea Pérez-Iturralde, Beatriz Carte, and Rafael Aldabe18 October 2021 | Human Gene Therapy, Vol. 32, No. 19-20Newborn screening of neuromuscular diseasesNeuromuscular Disorders, Vol. 31, No. 10X-linked myotubular myopathyNeuromuscular Disorders, Vol. 31, No. 10Genetic therapy for congenital myopathies13 July 2021 | Current Opinion in Neurology, Vol. 34, No. 5Gene therapy for hemophilia: a review on clinical benefit, limitations, and remaining issues7 July 2021 | Blood, Vol. 138, No. 11A sensitive and reproducible cell-based assay via secNanoLuc to detect neutralizing antibody against adeno-associated virus vector capsidMolecular Therapy - Methods & Clinical Development, Vol. 22Viral gene therapy for paediatric neurological diseases: progress to clinical reality9 April 2021 | Developmental Medicine & Child Neurology, Vol. 63, No. 9Intracranial hemorrhage secondary to vitamin K deficiency in X-linked myotubular myopathyNeuromuscular Disorders, Vol. 31, No. 7Restoring Protein Expression in Neuromuscular Conditions: A Review Assessing the Current State of Exon Skipping/Inclusion and Gene Therapies for Duchenne Muscular Dystrophy and Spinal Muscular Atrophy7 June 2021 | BioDrugs, Vol. 35, No. 4VectorMOD: Method for Bottom-Up Proteomic Characterization of rAAV Capsid Post-Translational Modifications and Vector Impurities1 April 2021 | Frontiers in Immunology, Vol. 12Immunomodulation in Administration of rAAV: Preclinical and Clinical Adjuvant Pharmacotherapies1 April 2021 | Frontiers in Immunology, Vol. 12Safety Monitoring of Gene Therapy for Spinal Muscular Atrophy with Onasemnogene Abeparvovec –A Single Centre ExperienceJournal of Neuromuscular Diseases, Vol. 8, No. 2Challenges at the Crossroads: Myopathy Trials in 2020 HindsightMolecular Therapy, Vol. 29, No. 2Severe offtarget effects following intravenous delivery of AAV9-MECP2 in a female mouse model of Rett syndromeNeurobiology of DiseaseWhen the Capsid Meets the Promoter: A New Insight into Transgene Expression from Adeno-Associated Virus Vectors Arun Srivastava13 November 2020 | Human Gene Therapy, Vol. 31, No. 21-22The Platform Vector Gene Therapies Project: Increasing the Efficiency of Adeno-Associated Virus Gene Therapy Clinical Trial Startup Philip J. Brooks, Elizabeth A. Ottinger, Deanna Portero, Richa Madan Lomash, Asaf Alimardanov, Pramod Terse, Xin Xu, Randy J. Chandler, Janelle Geist Hauserman, Eric Esposito, Carsten G. Bönnemann, Charles P. Venditti, Christopher P. Austin, Anne Pariser, Donald C. Lo, , Gilberto V. Averion, Krishna Balakrishnan, Steven J. Burden, Eggerton Campbell, Catherine Chen, Claire Driscoll, Oksana Dukhanina, Susan Ferry, A. Reghan Foley, Lina Li, Irini Manoli, Christopher Mendoza, Julien Oury, Forbes D. Porter, Lili Portilla, Dimah Saade, Oleg A. Shchelochkov, Jennifer L. Sloan, Joshua Todd, London Toney, Carol Van Ryzin, Sury Vepa, Erik Wagner, and Amy Wang16 October 2020 | Human Gene Therapy, Vol. 31, No. 19-20 Volume 31Issue 15-16Aug 2020 Information© Perry B. Shieh et al., 2020; Published by Mary Ann Liebert, Inc.To cite this article:Perry B. Shieh, Carsten G. Bönnemann, Wolfgang Müller-Felber, Astrid Blaschek, James J. Dowling, Nancy L. Kuntz, and Andreea M. Seferian.Re: "Moving Forward After Two Deaths in a Gene Therapy Trial of Myotubular Myopathy" by Wilson and Flotte.Human Gene Therapy.Aug 2020.787-787.http://doi.org/10.1089/hum.2020.217creative commons licensePublished in Volume: 31 Issue 15-16: August 17, 2020Online Ahead of Editing: August 10, 2020Open accessThis Open Access article is distributed under the terms of the Creative Commons License ( http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.PDF download